Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05694169 · ClinicalTrials.gov registry record · Phase 1
A Study of Participants With Chronic Kidney Disease Previously Treated With REACT
A Phase 1 study, sponsored by Prokidney.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT05694169: Clinical Trial Phase 1 study, sponsored by Prokidney.
NCT05694169 is a Phase 1 study that was terminated before completion, run by Prokidney. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05694169, a Phase 1 study, was terminated before completion, sponsored by Prokidney.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of supplemental REACT injections in participants with chronic kidney disease (CKD) who have previously received REACT treatment.
Primary Outcome
Procedure and investigational product-related treatment-emergent adverse events (TEAE) will be assessed via: 1. Biopsy Related SAEs 2. Injection Procedure Related SAEs 3. Investigational Product Related SAEs 4. Treatment-Emergent SAEs.
Interventions
- BIOLOGICAL Renal Autologous Cell Therapy (REACT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-07-11 |
| Est. Completion | 2024-05-13 |
| Phase | Phase 1 |
Why NCT05694169 stopped before completion
NCT05694169 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Renal Autologous Cell Therapy (REACT) is the first listed.
NCT05694169 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05694169 about?
NCT05694169 is a clinical study titled "A Study of Participants With Chronic Kidney Disease Previously Treated With REACT". The purpose of this study is to evaluate the safety of supplemental REACT injections in participants with chronic kidney disease (CKD) who have previously received REACT treatment.
What is the current status of trial NCT05694169?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2023-07-11. Estimated completion is 2024-05-13.
What interventions are being tested in trial NCT05694169?
The interventions under investigation include: Renal Autologous Cell Therapy (REACT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05694169?
This trial is sponsored by Prokidney, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05694169's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI